United States · 
Who invested in Exonics Therapeutics?
Exonics Therapeutics's investors include CureDuchenne Ventures and The Collumn Group.
2018
$5.0MSeed$40MSeries AUnited States · Series A startup
Who invested in Exonics Therapeutics
2 rounds we have observed, with the 2 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Funding summaryUpdated 26 Oct 2026
$45Mraised across 2 rounds since 2017, from 2 sources
$5.0MSeed$40MSeries A
- Latest round
- Series A, $40MNov 2017
- Step-upi
- 8×
- Investors
- 2
The funding story
Each circle is a round, placed by date and sized by amount. The line above is the running total.
- First round
- Seed, $5.0M Feb 2017
- Biggest round
- $40M Series A · Nov 2017
- Between rounds
- 8 months from the last two
The rounds
- Nov 2017
- Feb 2017
Who was in which round
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Everyone who backed them
The Collumn Groupno record of our own yet1round
Missing a round, or an investor who was in one? Tell us.
Quick answers about Exonics Therapeutics
How much has Exonics Therapeutics raised?
Exonics Therapeutics has raised $45M across 2 rounds since 2017.
When did Exonics Therapeutics last raise?
Exonics Therapeutics's most recent round was a Series A of $40M in Nov 2017.
What was Exonics Therapeutics's biggest round?
Its most recent round, $40M in Nov 2017, is also its largest on record.
Who backed Exonics Therapeutics first?
Exonics Therapeutics's first round on record, in Feb 2017, was backed by CureDuchenne Ventures.
What stage is Exonics Therapeutics at?
Exonics Therapeutics's latest named round is a Series A, in Nov 2017.
Where is Exonics Therapeutics based?
Exonics Therapeutics is based in the United States.
Companies like Exonics Therapeutics
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.